ZEMAIRA® Alpha-1 Proteinase Inhibitor (Human) Update, Approval of Thermo Fisher

“The Alpha-1 Foundation is pleased with the recent developments that have come to fruition, this is exciting and significant news for the health and well-being of the Alpha-1 patient community. The FDA approved partnership between CSL Behring and Thermo Fisher delivers the manufacturing capabilities essential to offer necessary supply to patients into the future. “- Scott Santarella, Alpha-1 Foundation President & CEO

February 3, 2022 – At CSL Behring, patient focus is our fundamental and guiding company principle. We take our commitment to patients very seriously and remain fully committed to supporting the patient community and manufacturing adequate supply of ZEMAIRA to meet the needs of patients.

We are pleased to share that the U.S. Food and Drug Administration (FDA) approved an additional manufacturing site to expand our supply capabilities of ZEMAIRA. We now expect additional product availability to meet present and future demand and are urgently working to provide consistent ZEMAIRA supply to customers. We will continue to provide ongoing updates on ZEMAIRA.